Articles Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate SELECTMONOTHERAPY a randomised placebocontrolled doubleblind phase 3 study

[Articles] Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

20:30 EDT 23 May 2019 | The Lancet

Upadacitinib monotherapy showed statistically significant improvements in clinical and functional outcomes versus continuing methotrexate in this methotrexate inadequate-responder population. Safety observations were similar to those in previous upadacitinib rheumatoid arthritis studies.

More From BioPortfolio on "[Articles] Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study"